Your browser doesn't support javascript.
loading
Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women.
Chung, Tony K H; Van Hummelen, Paul; Chan, Paul K S; Cheung, Tak Hong; Yim, So Fan; Yu, Mei Y; Ducar, Matthew D; Thorner, Aaron R; MacConaill, Laura E; Doran, Graeme; Pedamallu, Chandra Sekhar; Ojesina, Akinyemi I; Wong, Raymond R Y; Wang, Vivian W; Freeman, Samuel S; Lau, Tat San; Kwong, Joseph; Chan, Loucia K Y; Fromer, Menachem; May, Taymaa; Worley, Michael J; Esselen, Katharine M; Elias, Kevin M; Lawrence, Michael; Getz, Gad; Smith, David I; Crum, Christopher P; Meyerson, Matthew; Berkowitz, Ross S; Wong, Yick Fu.
Afiliação
  • Chung TK; Department of Obstetrics & Gynaecology, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
  • Van Hummelen P; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Chan PK; Department of Microbiology, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
  • Cheung TH; Department of Obstetrics & Gynaecology, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
  • Yim SF; Department of Obstetrics & Gynaecology, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
  • Yu MY; Department of Anatomical & Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
  • Ducar MD; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Thorner AR; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • MacConaill LE; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Doran G; Department of Pathology, Harvard Medical School, Boston, MA.
  • Pedamallu CS; Cancer Program, The Broad Institute of MIT and Harvard University, Cambridge, MA.
  • Ojesina AI; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Wong RR; Cancer Program, The Broad Institute of MIT and Harvard University, Cambridge, MA.
  • Wang VW; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Freeman SS; Harvard Medical School, Pediatric Surgical Laboratories, Massachusetts General Hospital, Boston, MA.
  • Lau TS; Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN.
  • Kwong J; Cancer Program, The Broad Institute of MIT and Harvard University, Cambridge, MA.
  • Chan LK; Department of Obstetrics & Gynaecology, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
  • Fromer M; Department of Obstetrics & Gynaecology, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
  • May T; Department of Obstetrics & Gynaecology, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
  • Worley MJ; Division of Psychiatric Genomics, Mount Sinai School of Medicine, New York, NY.
  • Esselen KM; Division of Gynecologic Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada.
  • Elias KM; Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Lawrence M; Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Getz G; Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Smith DI; Cancer Genomics Informatics and Computational Biology, The Broad Institute of Harvard and MIT, Cambridge, MA.
  • Crum CP; Cancer Genomics Informatics and Computational Biology, The Broad Institute of Harvard and MIT, Cambridge, MA.
  • Meyerson M; Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN.
  • Berkowitz RS; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Wong YF; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Int J Cancer ; 137(4): 776-83, 2015 Aug 15.
Article em En | MEDLINE | ID: mdl-25626421
ABSTRACT
Although the rates of cervical squamous cell carcinoma have been declining, the rates of cervical adenocarcinoma are increasing in some countries. Outcomes for advanced cervical adenocarcinoma remain poor. Precision mapping of genetic alterations in cervical adenocarcinoma may enable better selection of therapies and deliver improved outcomes when combined with new sequencing diagnostics. We present whole-exome sequencing results from 15 cervical adenocarcinomas and paired normal samples from Hong Kong Chinese women. These data revealed a heterogeneous mutation spectrum and identified several frequently altered genes including FAT1, ARID1A, ERBB2 and PIK3CA. Exome sequencing identified human papillomavirus (HPV) sequences in 13 tumors in which the HPV genome might have integrated into and hence disrupted the functions of certain exons, raising the possibility that HPV integration can alter pathways other than p53 and pRb. Together, these provisionary data suggest the potential for individualized therapies for cervical adenocarcinoma based on genomic information.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Neoplasias do Colo do Útero / Sequenciamento de Nucleotídeos em Larga Escala Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Neoplasias do Colo do Útero / Sequenciamento de Nucleotídeos em Larga Escala Limite: Adult / Aged / Female / Humans / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2015 Tipo de documento: Article